rivastigmine has been researched along with scutellarein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ang, W; Deng, Y; Li, Y; Liu, Q; Luo, Y; Qiang, X; Sang, Z; Shi, Y; Tan, Z; Yuan, W | 1 |
| Deng, Y; Li, Y; Qiang, XM; Sang, ZP; Wu, B; Zhang, H; Zhao, MG | 1 |
2 other study(ies) available for rivastigmine and scutellarein
| Article | Year |
|---|---|
Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Apigenin; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrogen Peroxide; Memory Disorders; Mice; Models, Molecular; Molecular Structure; PC12 Cells; Peptide Fragments; Rats; Scopolamine; Structure-Activity Relationship | 2015 |
Design, synthesis, and biological evaluation of scutellarein carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Brain; Butyrylcholinesterase; Carbamates; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Female; Humans; Male; Memory; Mice; Molecular Targeted Therapy; Neuroprotective Agents; PC12 Cells; Rats | 2015 |